Premium
CCDC85B promotes non‐small cell lung cancer cell proliferation and invasion
Author(s) -
Feng Yangyang,
Gao Yue,
Yu Juanhan,
Jiang Guiyang,
Zhang Xiupeng,
Lin Xuyong,
Han Qiang,
Rong Xuezhu,
Xu Hongtao,
Li Qingchang,
Qiu Xueshan,
Wang Enhua
Publication year - 2019
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.22914
Subject(s) - biology , downregulation and upregulation , cancer research , gene knockdown , cyclin d1 , cell growth , wnt signaling pathway , lung cancer , protein kinase b , pi3k/akt/mtor pathway , ly294002 , metastasis , a549 cell , catenin , cell , cancer , cell culture , phosphorylation , signal transduction , cell cycle , microbiology and biotechnology , pathology , medicine , gene , biochemistry , genetics
Coiled‐coil domain containing 85 B (CCDC85B) is involved in diverse biological processes; however, its expression patterns and functions in human cancers are yet unknown. The present study demonstrated that the expression of CCDC85B in the cytoplasm of the non‐small cell lung cancer (NSCLC) tumor cells was significantly higher compared to adjacent normal lung tissues ( P < 0.05). Furthermore, CCDC85B expression correlated with advanced TNM stage ( P = 0.004) and positive regional lymph node metastasis ( P = 0.009) of NSCLC. In addition, in A549 and H1299 lung cancer cell lines, the overexpression of CCDC85B promoted cell proliferation and invasion, while siRNA‐mediated CCDC85B knockdown exhibited opposite effects. CCDC85B promoted AKT and GSK3β phosphorylation and upregulated the levels of active β‐catenin, Wnt targets c‐myc, cyclin D1, and MMP7. Besides, the CCDC85B‐induced upregulation of phosphorylated GSK3β and active β‐catenin was rescued following the treatment with PI3 K inhibitor, LY294002. In conclusion, CCDC85B was associated with NSCLC progression as it promoted the proliferation and invasion of lung cancer cells through activated AKT/GSK3β/β‐catenin oncogenic signaling pathway. Therefore, CCDC85B might serve as a novel target for NSCLC treatment.